First Affirmative Financial Network Has $261,000 Position in Sanofi (NASDAQ:SNY)

First Affirmative Financial Network decreased its holdings in shares of Sanofi (NASDAQ:SNY) by 6.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,526 shares of the company’s stock after selling 300 shares during the quarter. First Affirmative Financial Network’s holdings in Sanofi were worth $261,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in SNY. POM Investment Strategies LLC bought a new position in shares of Sanofi during the second quarter worth approximately $25,000. Larson Financial Group LLC increased its position in Sanofi by 480.8% during the 1st quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock worth $29,000 after buying an additional 500 shares during the period. Register Financial Advisors LLC acquired a new stake in shares of Sanofi during the first quarter worth $29,000. Palisade Asset Management LLC bought a new stake in shares of Sanofi in the first quarter valued at about $31,000. Finally, Arrow Financial Corp acquired a new position in shares of Sanofi in the second quarter valued at about $35,000. 10.04% of the stock is owned by institutional investors.

Sanofi Trading Up 0.3 %

Shares of Sanofi stock opened at $54.96 on Friday. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. Sanofi has a 12-month low of $42.63 and a 12-month high of $58.97. The company has a market capitalization of $139.46 billion, a price-to-earnings ratio of 29.87, a PEG ratio of 1.57 and a beta of 0.60. The firm’s 50-day moving average price is $55.81 and its two-hundred day moving average price is $51.34.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business had revenue of $10.75 billion for the quarter, compared to analyst estimates of $16.86 billion. During the same quarter last year, the business posted $0.95 EPS. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. On average, analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several analysts have weighed in on SNY shares. Argus lifted their price objective on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a research note on Friday, July 26th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Finally, StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 8th. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.